middle.news
How Is Recce Advancing Its $85M R&D-Backed Phase 3 Trial in Indonesia?
1:26pm on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
How Is Recce Advancing Its $85M R&D-Backed Phase 3 Trial in Indonesia?
1:26pm on Friday 30th of January, 2026 AEDT
Key Points
Phase 3 clinical trial for diabetic foot infections underway in Indonesia
Positive preclinical efficacy of inhaled RECCE 327 against pneumonia in mice
Hong Kong patent granted for RECCE anti-infectives, expanding IP footprint
Received AUD 5.3 million R&D tax rebate with AUD 3.5 million expected
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE